One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes
Manfredi Rizzo, Francesco Cosentino & Christos Mantzoros
doi : 10.1080/17512433.2022.2108400
Expert Review of Clinical Pharmacology, Volume 15, Issue 7 (2022)
Dasiglucagon for treating severe hypoglycemia in patients with diabetes
Yongjing Ju, Duzhen Zhang & Junyi Yang
doi : 10.1080/17512433.2022.2103537
Diabetic patients are prone to hypoglycemia when treated with insulin. Dasiglucagon is a water-soluble and ready-to-use glucagon analog developed for treating hypoglycemia in patients with diabetes.
Reliance is key to effective access and oversight of medical products in case of public health emergencies
Agnes Saint-Raymond, Marie Valentin, Nobumasa Nakashima, Nick Orphanos, Gustavo Santos, Georgios Balkamos & Samvel Azatyan
doi : 10.1080/17512433.2022.2088503
Responding to new threats and public health emergencies (PHE) creates serious challenges to regulators. The pandemic due to SARS-CoV-2 has been the catalyzer for change in global and local regulatory practices. Intensified collaboration, rapid and coordinated actions, and reliance mechanisms were key elements of the regulators’ response to COVID-19 for all regulatory functions.
The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack
John H McDermott, Marc Leach, Dwaipayan Sen, Craig J. Smith, William G. Newman & Philip M. Bath
doi : 10.1080/17512433.2022.2108401
Clopidogrel is an antiplatelet agent recommended for secondary prevention of ischemic stroke (IS) and transient ischemic attack (TIA). Conversion of clopidogrel to its active metabolite by hepatic cytochrome P450-2C19 (CYP2C19) is essential for the inhibition of the P2Y12 receptor and subsequent platelet aggregation to prevent thrombotic events. CYP2C19 is highly polymorphic, with over 30 loss of function (LoF) alleles.
Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria
Nasir Shah, Vlado Perkovic & Sradha Kotwal
doi : 10.1080/17512433.2022.2108402
Diabetes is the most common cause of end-stage kidney disease. Therapies such as sodium-glucose co-transporter-2 inhibitors have been identified over the last decade as effective oral hypoglycemic agents that also confer additional cardio and kidney protection. Knowledge of their mechanism of action and impact on patients with diabetes and albuminuria is vital in galvanizing prescriber confidence and increasing clinical uptake.
Therapeutic approach to neurological manifestations of Angelman syndrome
Michele Ascoli, Maurizio Elia, Sara Gasparini, Paolo Bonanni, Giovanni Mastroianni, Vittoria Cianci, Sabrina Neri, Angelo Pascarella, Domenico Santangelo, Umberto Aguglia & Edoardo Ferlazzo
doi : 10.1080/17512433.2022.2109463
Angelman syndrome (AS) is a neurogenetic disorder due to deficient expression of the maternal copy of the UBE3A gene, which encodes ubiquitin ligase E3A protein. Severe developmental delay, seizures and other neurological disorders characterize AS.
The role of the alternative pathway in paroxysmal nocturnal hemoglobinuria and emerging treatments
Jong Wook Lee, Robert A. Brodsky, Jun-Ichi Nishimura & Austin G. Kulasekararaj
doi : 10.1080/17512433.2022.2109462
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by uncontrolled activation of the terminal complement pathway, leading to intravascular hemolysis (IVH) and a prothrombotic state. Treatment with terminal complement (C5) inhibitors, the current standard of care, suppresses IVH and reduces the risk of thrombosis and the associated morbidity and mortality. Opportunities exist to further improve care by alternative modes of administration and the reduction of clinically significant anemia and transfusion dependence caused by extravascular hemolysis in some patients.
Pharmacological approaches to prevent vertical transmission of HIV and HBV
Emanuela Zappulo, Agnese Giaccone, Nicola Schiano Moriello & Ivan Gentile
doi : 10.1080/17512433.2022.2105202
Mother-to-child transmission (MTCT) is mainly responsible for the global pediatric HIV and HBV epidemic. Vertical transmission can be prevented and reduced through a series of interventions at the primary healthcare level, including extensive screening of pregnant women, administration of antivirals or immune-based treatments, counselling on type of delivery and breastfeeding.
The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysis
Yunke Ma, Chu Lin, Xiaoling Cai, Suiyuan Hu, Xingyun Zhu, Fang Lv, Wenjia Yang & Linong Ji
doi : 10.1080/17512433.2022.2102973
To assess the association between the use of sodium–glucose cotransporter 2 inhibitor (SGLT2i) and the incidence of diabetic retinopathy (DR).
Comparison of the relative efficacy of different biologics in different body areas in patients with moderate to severe psoriasis receiving biologics and tofacitinib in phase 3 randomized controlled trials: a 15-year single-center experience
Chen-Pu Yeh, Yi-Wei Huang & Tsen-Fang Tsai
doi : 10.1080/17512433.2022.2103538
Focal resistant plaques are still common despite the use of biologics for psoriasis. significant impact on quality of life.
Regional variation in longitudinal trajectories of primary care opioids prescribing across Health Boards in Scotland: a population-based study
Teng-Chou Chen, Amanj Kurdi, Ting-Li Su & Li-Chia Chen
doi : 10.1080/17512433.2022.2102972
This study aims to describe the longitudinal trajectory of opioid prescribing at the practice level and assess associated factors, including Health Boards and socioeconomic status.
